Vitamin Shoppe Inc (NYSE:VSI) has been assigned an average recommendation of “Hold” from the ten brokerages that are currently covering the company. Two investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $29.29.
A number of equities research analysts have recently weighed in on VSI shares. Zacks Investment Research raised shares of Vitamin Shoppe from a “sell” rating to a “buy” rating and set a $27.00 price objective on the stock in a report on Friday, January 6th. Goldman Sachs Group Inc dropped their price objective on shares of Vitamin Shoppe from $22.00 to $19.00 and set a “sell” rating on the stock in a report on Thursday, March 23rd. Finally, Morgan Stanley downgraded shares of Vitamin Shoppe from an “equal weight” rating to an “underweight” rating and set a $22.00 target price for the company. in a research report on Tuesday, January 17th.
COPYRIGHT VIOLATION NOTICE: “Vitamin Shoppe Inc (VSI) Receives $29.38 Consensus Target Price from Analysts” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/04/21/vitamin-shoppe-inc-vsi-receives-29-38-average-pt-from-analysts-updated.html.
Vitamin Shoppe (NYSE:VSI) traded down 2.46% on Tuesday, hitting $19.85. The company’s stock had a trading volume of 126,981 shares. Vitamin Shoppe has a 12 month low of $18.25 and a 12 month high of $32.31. The firm has a market cap of $457.56 million, a price-to-earnings ratio of 19.09 and a beta of 0.59. The firm has a 50 day moving average of $19.54 and a 200 day moving average of $23.11.
Vitamin Shoppe (NYSE:VSI) last released its quarterly earnings results on Wednesday, March 1st. The specialty retailer reported $0.36 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.40 by $0.04. The firm earned $304.87 million during the quarter, compared to analysts’ expectations of $311.79 million. Vitamin Shoppe had a return on equity of 11.52% and a net margin of 3.34%. Vitamin Shoppe’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.39 earnings per share. Equities research analysts forecast that Vitamin Shoppe will post $2.05 earnings per share for the current fiscal year.
In other news, Director Richard L. Markee sold 100,000 shares of the business’s stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $22.24, for a total transaction of $2,224,000.00. Following the completion of the sale, the director now owns 160,990 shares of the company’s stock, valued at $3,580,417.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Dan Lamadrid sold 5,432 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $22.36, for a total transaction of $121,459.52. Following the completion of the transaction, the chief accounting officer now owns 16,817 shares in the company, valued at $376,028.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,161 shares of company stock valued at $2,398,429. Insiders own 1.29% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Municipal Employees Retirement System of Michigan raised its stake in Vitamin Shoppe by 1.5% in the third quarter. Municipal Employees Retirement System of Michigan now owns 5,380 shares of the specialty retailer’s stock worth $144,000 after buying an additional 80 shares during the period. Stevens Capital Management LP raised its stake in Vitamin Shoppe by 4.7% in the third quarter. Stevens Capital Management LP now owns 10,733 shares of the specialty retailer’s stock worth $288,000 after buying an additional 479 shares during the period. Comerica Bank raised its stake in Vitamin Shoppe by 5.1% in the fourth quarter. Comerica Bank now owns 25,654 shares of the specialty retailer’s stock worth $590,000 after buying an additional 1,246 shares during the period. First Trust Advisors LP raised its stake in Vitamin Shoppe by 6.6% in the third quarter. First Trust Advisors LP now owns 58,168 shares of the specialty retailer’s stock worth $1,562,000 after buying an additional 3,618 shares during the period. Finally, Martingale Asset Management L P raised its stake in Vitamin Shoppe by 5.2% in the fourth quarter. Martingale Asset Management L P now owns 136,623 shares of the specialty retailer’s stock worth $3,245,000 after buying an additional 6,799 shares during the period.
Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, which includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats; direct, which sells its products directly to consumers through the Internet, primarily at www.vitaminshoppe.com, and manufacturing, which provides custom manufacturing and private labeling of vitamin, mineral and supplement (VMS) products.
Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.